Gregory K. Palm
Direktor/Vorstandsmitglied bei Olatec Therapeutics LLC
Aktive Positionen von Gregory K. Palm
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Olatec Therapeutics LLC
Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Direktor/Vorstandsmitglied | 29.07.2021 | - |
Karriereverlauf von Gregory K. Palm
Ehemalige bekannte Positionen von Gregory K. Palm
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
THE GOLDMAN SACHS GROUP, INC. | General Counsel | 01.05.1992 | - |
Unternehmenssekretär | 01.05.1992 | - |
Ausbildung von Gregory K. Palm
Harvard Business School | Graduate Degree |
Massachusetts Institute of Technology | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
General Counsel | 1 |
Corporate Secretary | 1 |
Director/Board Member | 1 |
Sektoral
Finance | 3 |
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
THE GOLDMAN SACHS GROUP, INC. | Finance |
Private Unternehmen | 1 |
---|---|
Olatec Therapeutics LLC
Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Health Technology |
- Börse
- Insiders
- Gregory K. Palm
- Erfahrung